Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?

The Changing Fortunes of Telemedicine in Europe – Past, Present, and Future beyond COVID-19

US SARS-CoV-2 Testing Response: What can be learned from South Korea and Germany?

Medtech Geographic Launch Sequences Warrant Reevaluation

e-Health in France: Spotlight on the National Healthcare Digitalization Strategy

ATTD 2020 – Transforming Diabetes Care Through Technology

Bridging the Gap in Clinical and Economic Evidence for Digital Health Tech in the UK

Key Takeaways from ESMO 2019

E-Health in Germany: Three New Laws Signify the Imminent Transformation to a Digitalised Healthcare System

Health Advances Presentation at ISPOR: Findings from the First Five Years of the NICE HST Program for Ultra Rare Conditions

E-Health in Germany: Rapid Progression of Digitalisation?

New Assessment Pathway for Invasive High-Risk Medical Devices in Germany: Balancing Market Access, Evidence and Patient Benefit

Disease Management Programs (DMPs) in Germany: The Importance of Guideline Inclusion for Chronic Therapies

The Medicines Optimisation Program in England

Early Access Programs in Europe: Differences and Opportunities in Germany, France and the UK

Patient Advocacy Groups as a Strategy for Orphan Drug Access in the UK

PCSK9 Inhibitors’ Battle for Reimbursement: Germany’s Decision and Implications in Other Countries

Rare Disease Prevalence and Orphan Drug Pricing in Europe

The Accelerated Access Review in the UK: Quicker Access to Innovative Drugs and Diagnostics, Medical and Digital Technologies

The Accelerated Access Review in the UK: Quicker Access to Innovative Drugs and Diagnostics, Medical and Digital Technologies

Health Advances Blog

Category: European Markets

Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?

The Changing Fortunes of Telemedicine in Europe – Past, Present, and Future beyond COVID-19

US SARS-CoV-2 Testing Response: What can be learned from South Korea and Germany?

Medtech Geographic Launch Sequences Warrant Reevaluation

e-Health in France: Spotlight on the National Healthcare Digitalization Strategy

ATTD 2020 – Transforming Diabetes Care Through Technology

Bridging the Gap in Clinical and Economic Evidence for Digital Health Tech in the UK

Key Takeaways from ESMO 2019

E-Health in Germany: Three New Laws Signify the Imminent Transformation to a Digitalised Healthcare System

Health Advances Presentation at ISPOR: Findings from the First Five Years of the NICE HST Program for Ultra Rare Conditions

E-Health in Germany: Rapid Progression of Digitalisation?

New Assessment Pathway for Invasive High-Risk Medical Devices in Germany: Balancing Market Access, Evidence and Patient Benefit

Disease Management Programs (DMPs) in Germany: The Importance of Guideline Inclusion for Chronic Therapies

The Medicines Optimisation Program in England

Early Access Programs in Europe: Differences and Opportunities in Germany, France and the UK

Patient Advocacy Groups as a Strategy for Orphan Drug Access in the UK

PCSK9 Inhibitors’ Battle for Reimbursement: Germany’s Decision and Implications in Other Countries

Rare Disease Prevalence and Orphan Drug Pricing in Europe

The Accelerated Access Review in the UK: Quicker Access to Innovative Drugs and Diagnostics, Medical and Digital Technologies

The Accelerated Access Review in the UK: Quicker Access to Innovative Drugs and Diagnostics, Medical and Digital Technologies